Absolute bioavailability of letrozole in healthy postmenopausal women
โ Scribed by A. Sioufi; N. Gauducheau; V. Pineau; F. Marfil; A. Jaouen; J. M. Cardot; J. Godbillon; C. Czendlik; H. Howald; CH. Pfister; F. Vreeland
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 143 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0142-2782
No coin nor oath required. For personal study only.
โฆ Synopsis
Letrozole is a new non-steroidal inhibitor of the aromatase enzyme system. It is currently under development for the treatment of postmenopausal women with advanced breast cancer. Absolute bioavailability of letrozole when given orally as one 2ยด5 mg ยฎlm-coated tablet in comparison to the same dose given intravenously as a bolus injection was studied in 12 healthy postmenopausal women. Letrozole absolute systemic bioavailability after p.o. administration was 99ยด9+16ยด3%. Elimination of letrozole was slow. Total-body clearance of letrozole from plasma after i.v. administration was low (2.21 L h 71 ). The calculated distribution volume at steady state (1.87 L kg 71 ) suggests a rather high tissue distribution. Biotransformation of letrozole is the main elimination mechanism with the glucuronide conjugate of the secondary alcohol metabolite being the predominant species found in urine. The two study treatments were tolerated equally well. &1997 John Wiley & Sons, Ltd.
๐ SIMILAR VOLUMES
Sclerostin is a secreted Wnt antagonist produced almost exclusively by osteocytes that regulates bone mass. However, there is currently limited information on the determinants of sclerostin in a large population-based study. The main objectives of the present study were to: (1) establish reference n
Eighteen healthy males received a single 300 mg oral dose of eprosartan as the commercial wet granulation formulation under fasting conditions and following a high-fat breakfast and a single 20 mg intravenous (i.v.) dose. The pharmacokinetics of i.v. eprosartan (mean 9 S.D.) were characterized by a
Letrozole is a new non-steroidal inhibitor of the aromatase enzyme system. It is currently under development for the treatment of postmenopausal women with advanced breast cancer. To investigate the inยฏuence of food on the bioavailability of letrozole, 12 healthy male volunteers were treated under f